Clopidogrel Versus Aspirin Monotherapy According to Atherothrombotic Risk Profile
Authors' conclusion
After completion of dual antiplatelet therapy following PCI, clopidogrel monotherapy was associated with lower ischemic risk than aspirin in patients with higher atherothrombotic risk, without increased bleeding.
Study context
- Population
- Patients who completed guideline-directed dual antiplatelet therapy after percutaneous coronary intervention (PCI)higher risk 4,486 (81.5%) · lower risk 1,020 (18.5%)
- Participants
- 5,506 patients
- Comparison
- Clopidogrel versus aspirin monotherapy according to atherothrombotic risk profile
- Higher riskn = 4,486
- Lower riskn = 1,020reference
- Primary endpoint
- major adverse cardiac and cerebrovascular events (death, myocardial infarction, or stroke)
- Follow-up
- Median 2.3 years
Primary result
As reported in the abstract
Hazard ratio (95% CI)P value
Higher riskvs lower risk
1.83(1.17–2.78)
P = 0.007Clopidogrelvs aspirinhigher-risk patients: 4.6% versus 7.4%
0.67(0.50–0.89)
P = 0.006- Clopidogrel vs aspirin · lower-risk patients: 3.0% versus 3.2%
- hazard ratio 1.03; P = 0.945
Further findings
Bleeding (Bleeding Academic Research Consortium type 2, 3, or 5)
- Bleeding was similar between groups.
Original publication
Clopidogrel Versus Aspirin Monotherapy According to Atherothrombotic Risk Profile. Circ Cardiovasc Interv. Published 29 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →